title: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.
abstract: BACKGROUND
  The purpose of this study was to evaluate the prognostic value of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in patients with stage I pulmonary adenocarcinoma.
  
  
  METHODS
  A total of 139 consecutive patients with pathologic stage I pulmonary adenocarcinoma were retrospectively reviewed. Expression of LAT1, CD98, Ki-67 labeling index, vascular endothelial growth factor (VEGF) and microvessel density (MVD) was also evaluated immunohistochemically and correlated with the prognosis of patients after complete resection of the tumor.
  
  
  RESULTS
  LAT1 and CD98 expression were positive in 23% (32/139) and 22% (31/139), respectively (p=0.887). LAT1 with CD98 expression was recognized in 15% (21/139). LAT1 expression was significantly correlated with CD98, Ki-67 labeling index, VEGF, and MVD. The 5-year survival rates of LAT1-positive and -negative patients and CD98-positive and -negative patients, were 60.2 and 95.2% (p<0.0001) and 72.5 and 93.4% (p=0.0008), respectively. Univariate analysis disclosed that cellular proliferation and MVD in the tumor were significant prognostic factors. However, multivariate analysis confirmed that positive expression of LAT1 and CD98 was an independent factor for predicting a poor prognosis.
  
  
  CONCLUSIONS
  The overexpression of LAT1 and CD98 is a pathological factor to predict the prognosis in patients with resectable stage I pulmonary adenocarcinoma.
authors.affiliation: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan. kkaira1970@yahoo.co.jp
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Noboru
authors.initials: N
authors.lastname: Oriuchi
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Shimizu
authors.forename: Noriko
authors.initials: N
authors.lastname: Yanagitani
authors.forename: Noriaki
authors.initials: N
authors.lastname: Sunaga
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hisada
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Ishizuka
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Kanai
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Masatomo
authors.initials: M
authors.lastname: Mori
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D027282:Fusion Regulatory Protein 1, Heavy Chain / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D027283:Large Neutral Amino Acid-Transporter 1 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D027282:Fusion Regulatory Protein 1, Heavy Chain; D019394:Ki-67 Antigen; D027283:Large Neutral Amino Acid-Transporter 1; D042461:Vascular Endothelial Growth Factor A